

Protalix BioTherapeutics, Inc.  
Form 8-K  
August 13, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): August 13, 2018 (August 9, 2018)**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**



Exchange Act. "

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) On August 9, 2018, the Board of Directors of Protalix BioTherapeutics, Inc. (the “Company”) appointed Mr. David Granot to serve on the Company’s Board of Directors. In addition to Mr. Granot’s appointment as an independent director, he was also appointed to serve on the Company’s Audit Committee.

On August 13, 2018, the Company issued a press release announcing the appointment of Mr. Granot. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated August 13, 2018.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: August 13, 2018 By: /s/ Moshe Manor  
Name: Moshe Manor  
Title: President and Chief Executive Officer